# EDGAR Filing Document

**Accession Number:** 0001604924
**File Stem:** 0001171843-23-000358
**Filing Date:** 2023-1
**Character Count:** 6053
**Document Hash:** b4f1171979634c9cd5fe72d4003b29e3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-23-000358.hdr.sgml**: 20230120

**ACCESSION NUMBER**: 0001171843-23-000358

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230120

**DATE AS OF CHANGE**: 20230120

**EFFECTIVENESS DATE**: 20230120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Forward Pharma A/S
- **CENTRAL INDEX KEY:** 0001604924
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** G7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-203313
- **FILM NUMBER:** 23541477

**BUSINESS ADDRESS:**
- **STREET 1:** OSTERGADE 24A, 1
- **CITY:** COPENHAGEN
- **STATE:** G7
- **ZIP:** 1100
- **BUSINESS PHONE:** 0114533444242

**MAIL ADDRESS:**
- **STREET 1:** OSTERGADE 24A, 1
- **CITY:** COPENHAGEN
- **STATE:** G7
- **ZIP:** 1100

**As filed with the Securities and Exchange Commission on January 20, 2023**

**Registration No. 333-203313**

**Registration No. 333-261624**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**post-effective Amendment No. 1**

**To**

**FORM S-8**

**REGISTRATION STATEMENT NO. 333-203313**

**REGISTRATION STATEMENT NO. 333-261624**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**Forward Pharma A/S**

**(Exact name of registrant as specified in its charter)**

**Not Applicable**

**(Translation of registrant's name into English)**

---

| | |
|:---|:---|
| **Denmark** | **98-1228011** |
| **(State or other jurisdiction of** | **(I.R.S. Employer** |
| **incorporation or organization)** | **Identification Number)** |

---

**Østergade 24A, 1**

**1100 Copenhagen K, Denmark**

**+45 33 44 42 42**

**(Address of Principal Executive Offices Including Zip Code)**

**2014 Omnibus Equity Incentive Compensation Plan**

**STAND ALONE STOCK OPTION AWARDS**

**(Full Title of the Plans)**

**CT Corporation System**

**1015 15th Street, NW**

**Suite 1000**

**Washington, DC 20005**

**(202) 572-3100**

**(Name, address and telephone number of agent for service)**

*Copies to:*

**Ryan A. Murr**<br> **Gibson, Dunn & Crutcher LLP<br> 555 Mission St. Suite 3000<br> San Francisco, CA 94105**<br>

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻ Accelerated filer ◻ <br> Non-accelerated filer ⌧ Smaller reporting company ◻ <br> Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**DEREGISTRATION OF UNSOLD SECURITIES**

Forward Pharma A/S (the "Registrant") is filing this Post-Effective Amendment No. 1 (this "Amendment") to each of the following Registration Statements on Form S-8 (collectively, the "Registration Statements") to terminate all offerings under such Registration Statements and deregister any and all securities that remain unsold pursuant to the Registration Statements:

1. Registration Statement No. 333-203313, filed with the Securities and Exchange Commission (the "SEC") on April 9, 2015, registering the offer and sale of the Registrant's ordinary shares, nominal value DKK 0.01 per share, issuable pursuant to the 2014 Omnibus Equity Incentive Compensation Plan; and

2. Registration Statement No. 333-261624, filed with the SEC on December 13, 2021, registering the offer and sale of the Registrant's ordinary shares, nominal value DKK 0.01 per share, issuable pursuant to outstanding stock options granted outside of the Company's equity incentive plan.

The purpose of this Amendment is to deregister all remaining securities available for issuance under the Registration Statements. In accordance with the undertakings made by the Registrant in the Registration Statements to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused the Post-Effective Amendment No. 1 to the each of the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in Copenhagen, Denmark, on this 20th day of January, 2023.

---

| | |
|:---|:---|
| FORWARD PHARMA A/S | FORWARD PHARMA A/S |
| By: | /s/ Claus Bo Svendsen |
| Name: | Claus Bo Svendsen |
| Title: | Chief Executive Officer |

---

No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.

**SIGNATURE OF AUTHORIZED REPRESENTATIVE OF THE REGISTRANT**

Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Forward Pharma A/S, has signed this Post-Effective Amendment No. 1 to each of the Registration Statements on this 20th day of January, 2023.

---

| | |
|:---|:---|
| Forward Pharma USA, LLC | Forward Pharma USA, LLC |
| By: | /s/ Thomas Carbone |
| Name: | Thomas Carbone |
| Title: | Vice President, Finance and Controller |

---

No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.

------